Financial Performance - The company's operating revenue for the first half of 2023 was CNY 500,018,373.81, representing a 16.02% increase compared to CNY 430,974,648.13 in the same period last year[25]. - The net profit attributable to shareholders of the listed company reached CNY 54,254,541.64, up 20.92% from CNY 44,869,565.56 in the previous year[25]. - The net profit after deducting non-recurring gains and losses was CNY 51,297,897.29, reflecting a 10.55% increase from CNY 46,402,156.75 year-on-year[25]. - The basic earnings per share increased to CNY 0.58, an 11.54% rise compared to CNY 0.52 in the previous year[25]. - The diluted earnings per share also rose to CNY 0.58, marking a 16.00% increase from CNY 0.50[25]. - The net cash flow from operating activities decreased by 17.63% to CNY 59,688,440.80, down from CNY 72,461,969.55[25]. - The total revenue for the first half of 2023 was 1.5 billion, representing a year-on-year increase of 10%[189]. - The net profit attributable to shareholders for the same period was 270 million, up 8% compared to the previous year[189]. - The company reported a total revenue of CNY 70.071 billion for the first half of 2023, reflecting a growth of 22% compared to the previous year[192]. - The earnings per share (EPS) for the first half of 2023 was CNY 1.84, compared to CNY 1.70 in the same period last year, indicating a growth of 8.24%[192]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,931,230,495.54, a slight increase of 0.02% from CNY 1,930,786,964.46 at the end of the previous year[25]. - The company's fixed assets were valued at ¥337,575,917.60, which is 17.48% of total assets, down by 0.58% compared to the previous year[78]. - The total liabilities decreased to CNY 712,717,078.29 from CNY 983,183,297.68, indicating a reduction of about 27.4%[171]. - The capital reserve increased significantly to ¥532,705,566.48, accounting for 27.58% of total equity, up by 14.14% year-on-year, mainly due to the conversion of convertible bonds[78]. - The total equity attributable to shareholders at the end of the first half of 2023 was CNY 86.670 billion, up from CNY 86.271 billion at the end of the first half of 2022[191]. Research and Development - Research and development expenses surged by 157.75% to ¥10,619,580.97, reflecting a significant increase in investment in R&D[72]. - The company has allocated CNY 1.5 billion for R&D in 2023, which is a 10% increase from the previous year[192]. - The company is investing 100 million in R&D for new technologies aimed at enhancing product efficiency and user experience[189]. - The R&D platform is supported by a "scientist + engineer" team, enhancing the company's innovation capabilities in both traditional and modern medicine[66]. Market Strategy and Product Development - The company plans to continue expanding its market presence and investing in new product development to drive future growth[72]. - The company is focused on expanding its market presence and enhancing its research and development capabilities in the pharmaceutical sector[197]. - The company aims to achieve a dual 10 billion target through its "One Body, Two Wings" strategy, focusing on industrial development and health management[62]. - The company is actively pursuing market expansion strategies, particularly in the health and wellness sector, to capture a larger share of the growing demand for dietary supplements[47]. - The company plans to enhance its market strategy by developing potential products like Xiaer Yanbian Granules and Gushengbao Tablets, aiming for over 100 million RMB in market growth[94]. Regulatory and Industry Environment - The company operates in the traditional Chinese medicine sector, which is supported by national policies promoting its development[34]. - The aging population is driving demand for chronic disease medications, with 26.736 million people aged 60 and above in China as of 2021[35]. - Recent government policies emphasize the modernization and innovation of traditional Chinese medicine, indicating strong future support for the industry[36]. - The company faces risks from industry policy changes, which could adversely affect operations if strategies are not adjusted in response to new regulations and procurement policies[92]. - Increased market competition is a concern as both domestic and foreign companies expand their presence in China's pharmaceutical market, which is now the second largest globally[93]. Corporate Governance and Social Responsibility - The company actively engages with investors through various channels to ensure transparency and protect shareholder rights[105]. - The company complies with labor laws and has established a comprehensive internal system to protect employee rights and welfare[107]. - The company donated 1.02 million yuan to support the initial processing project of medicinal materials in the Mingxing community, addressing issues of economic development and technical shortages[108]. - The company actively participated in social charity activities, visiting families in need in various villages during the reporting period[108]. - The company is committed to rural revitalization and new rural construction, focusing on practical projects for community improvement[108]. Future Outlook - The company has outlined a positive outlook for the second half of 2023, projecting a revenue growth of 10% to 15%[114]. - Future guidance indicates a projected revenue growth of 12% for the next fiscal year, driven by new product launches and market expansion strategies[189]. - The management has provided guidance for the next quarter, expecting a revenue range of 400-450 million, reflecting continued growth momentum[189].

四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时 报告深圳证券交易所并按有关规定处理。 证券代码：002864 证券简称：盘龙药业 公告编号：2023-078 陕西盘龙药业集团股份有限公司 关于向特定对象发行股票申请获得中国证监会同意注册批复 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 陕西盘龙药业集团股份有限公司（以下简称"公司"）于近日收到中国证券 监督管理委员会（以下简称"中国证监会"）出具的《关于同意陕西盘龙药业集 团股份有限公司向特定对象发行股票注册的批复》（证监许可〔2023〕1709 号） （以下简称"批复"），批复主要内容如下： 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报文件和发行方案 实施。 三、本批复自同意注册之日起 12 个月内有效。 2023 年 8 月 11 日 公司董事会将根据上述文件和相关法律法规的要求及公司股东大会的授权， 在规定期限内办理本次向特定对象发行股票相关事宜，并及时履行信息披露义务。 敬请广大投资者注意投资风险。 本次向特定对象发行 ...

证券简称：盘龙药业 证券代码：002864 陕西盘龙药业集团股份有限公司 向特定对象发行 A 股股票 募集说明书 （注册稿） 保荐机构（主承销商） 济南市市中区经七路 86 号 二零二三年六月 1-1-1 陕西盘龙药业集团股份有限公司向特定对象发行 A 股股票 募集说明书 3、研发失败导致发行人盈利能力下降的风险 重大事项提示 公司特别提示投资者对下列重大风险给予充分关注，并仔细阅读本募集说明书中有 关风险因素的章节。 （一）高壁垒透皮给药系统研发平台建设项目研发风险 1、研发失败风险 医药产业链具有高度细分的特点，为提升透皮给药项目的研发效率和成功率，公司 顺应行业发展趋势，拟采用与 CRO 机构合作的形式进行。公司将委托 CRO 机构进行 阶段性、专业性的研究，并搭建自有团队，配备临床专员和观察员，掌握和管理研发进 度。公司已与博腾股份的全资子公司博腾药业签署协议，合作开发 PLJT-001 和 PLJT-002； 已与博济医药合作开发 PLJT-003，并已与博济医药全资子公司杏林中医药合作开发 PLJT-004。考虑到药品研发的风险性特征，包括技术工艺复杂，研发周期较长等特点， 尤其是，PLJT-00 ...

关于同意陕西盘龙药业集团股份有限公司 向特定对象发行股票注册的批复 陕西盘龙药业集团股份有限公司: 中国证券监督管理委员会收到深圳证券交易所报送的关于你 公司向特定对象发行股票的审核意见及你公司注册申请文件。根 据《中华人民共和国证券法》《中华人民共和国公司法》《国务院 办公厅关于贯彻实施修订后的证券法有关工作的通知》(国办发 〔2020〕5 号）和《上市公司证券发行注册管理办法》(证监会令 第 206号)等有关规定,经审阅深圳证券交易所审核意见及你公 司注册申请文件,现批复如下: 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送深圳证券交易所的申报 文件和发行方案实施。 三、本批复自同意注册之日起 12个月内有效。 中国证券监督管理委员会 证监许可〔2023〕1709 号 四、自同意注册之日起至本次发行结束前,你公司如发生重 2023 8 2 ...

证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|----------------------------|--------------------| | | | 编号：2023-05-16 | | 投资者关系活动 | □ 分析师会议 | | | 类别 | 业绩说明会 | | | | 路演活动 | | | | | | | | （请文字说明其他活动内容） | | | 参与单位名称及 | | | | 人员姓名 | | | | 时间 | 周二) 下午 15:00~17:00 | | | 地点 | | https://ir.p5w.net | | | | | | 上市公司接待人 | | | 员姓名医药研究院院长张德柱 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、医药行业市场竞争加剧，请问公司如何应对？ 尊敬的投资者您好！面对激烈的竞争格局，应该增加创新性 产品推出，加强中医药科学研究,中医药经典名方的研制，加强 中药资源保护利用，推进中药材规范化种植养殖， ...

关于参加"2023 年陕西辖区上市公司投资者集体接待日 暨 2022 年度业绩说明会"的公告 证券代码：002864 证券简称：盘龙药业 公告编号：2023-067 陕西盘龙药业集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为促进上市公司规范运作、健康发展，增强上市公司信息透明度，加强与广 大投资者的沟通交流，进一步提升投资者关系管理水平，陕西上市公司协会根据 陕西证监局工作部署，联合深圳市全景网络有限公司举办"2023 年陕西辖区上市 公司投资者集体接待日暨 2022 年度业绩说明会活动"。 届时，公司董事长及相关高管人员将通过互动平台与投资者进行网络沟通和 交流，欢迎广大投资者踊跃参加！ 活动时间：2023 年 5 月 16 日（星期二） 15:00-17:00。 陕西盘龙药业集团股份有限公司董事会 2023 年 5 月 11 日 活动地址："全景路演"。 网址：http://rs.p5w.net 。 特此公告。 ...

证券代码：002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司 投资者关系活动记录表 编号：2023-05-05 特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他 （请文字说明其他活动内容） 天风证券、国联证券、华安医药、申万元宏源证券、红土创新基金、西 藏源乘投资、长城证券、南方基金、招商基金、上投摩根基金、华宝基金、 博时基金、东方基金、前海开源、恒大人寿、长盛基金、东吴基金、浦银安 盛基金、东北证券、合众资产、中加基金、永安国富、云溪基金、中新融创、 参与单位名称 厦门金恒宇、东兴基金、云溪基金、江苏瑞华投资、泰康香港、上海途灵资 产、华夏久盈资产、上海域秀资产、中信保诚基金、西部利得基金、循远资 及人员姓名 产、上海方物私募、金信基金、西部利得基金、上海睿亿投资、信诚基金、 兴银理财、上海益理资产、上海运舟私募、金信基金、博道基金、上海楹联 投资、青骊投资管理、交银国际信托、国寿资产、上海原泽私募、浙江韶夏 投资、交通银行、Dymon Asia Capital (HK) 、LyGH 等 时间 2023 年 04 月 28 ...

证券代码： 002864 证券简称：盘龙药业 陕西盘龙药业集团股份有限公司投资者关系活动记录表 | --- | --- | |----------------|----------------------------| | 投资者关系活动 | □特定对象调研 | | 类别 | □ 媒体采访 √ | | | □ 新闻发布会 | | | □ 现场参观 | | | □ 其他 | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 8 日 ( | | 地点 | | | | 络远程的方式召开业绩说明会 | | 上市公司接待人 | | | 员姓名 | | | | 杨圣志 | 投资者提出的问题及公司回复情况 公司就投资者在本次说明会中提出的问题进行了回复： 1、请问盘龙 ESG 方面是如何规划的？ 尊敬的投资者您好！公司非常重视 ESG 工作的开展，目前此项公司分 两步走，第一步已经实施开展了企业社会责任报告的编制工作，并在 2022 年年度报告披露的同时，一同披露了公司 2022 年度履行社会责任报告， 投资者关系活动 后期持续开展 ESG 工作。感谢您的关注！ 主要内容 ...

证券代码： 002864 证券简称：盘龙药业 编号：2023-05-08 | 投资者关系活动 | □特定对象调研 分析师会议 □ | | --- | --- | | 类别 □ | 业绩说明会 媒体采访 √ | | □ | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 2023 年 5 月 8 日 (周一) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采用网 | | | 络远程的方式召开业绩说明会 | | 上市公司接待人 | 董事长兼总经理谢晓林、副总经理兼董事会秘书吴杰、财务总监祝凤鸣、 | | 员姓名 | 独立董事任海云、独立董事焦磊鹏、中泰证券投资银行业务委员会副总裁 | | | 杨圣志 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问盘龙 ESG 方面是如何规划的？ | | | 尊敬的投资者您好！公司非常重视 ...

Financial Performance - Shaanxi Panlong Pharmaceutical Group reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year increase of 15%[31]. - The company achieved a net profit of RMB 300 million in 2022, which is a 20% increase compared to the previous year[31]. - The company's operating revenue for 2022 was ¥974,293,135.49, representing a 9.78% increase from ¥887,484,877.11 in 2021[37]. - The net profit attributable to shareholders for 2022 was ¥101,163,536.29, an increase of 8.58% compared to ¥93,169,906.99 in 2021[37]. - The gross margin for 2022 was reported at 45%, reflecting improved operational efficiency[31]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2022, representing a year-on-year growth of 20%[165]. - The company achieved an annual revenue of ¥974,293,135.49, representing a year-on-year growth of 9.78%[95]. - The company plans to enhance its core competitiveness in traditional Chinese medicine while exploring product upgrades and innovation, focusing on "specialized, refined, unique, and new" strategies[150]. Product Development and Innovation - The company is expanding its product line and has successfully passed certification for health food and product workshops, enhancing its operational capacity[10]. - The company plans to launch three new products in 2023, focusing on traditional Chinese medicine, which is expected to contribute an additional RMB 200 million in revenue[31]. - The company is actively pursuing opportunities for market expansion and potential mergers and acquisitions to strengthen its competitive position[63]. - The company is developing several new products, including PLC-01 for coronavirus treatment and PLJT-001 for orthopedic pain management[120]. - The company has developed 23 health products and 2 medical devices, all of which have completed registration and are ready for market[98]. - The company plans to accelerate the research and development of innovative drugs, including the secondary development of major products and external medications, with a focus on traditional Chinese medicine granules and classic formulas[150]. - The company aims to enhance its innovation capabilities and strengthen the supply chain for high-end biopharmaceutical products as outlined in the national development plans[55]. Market Expansion and Strategy - The company aims to increase its market share by 10% in the next fiscal year through strategic partnerships and marketing initiatives[31]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[165]. - The company is set to launch three new products in Q3 2023, anticipated to contribute an additional 200 million RMB in revenue[165]. - The company aims to develop untapped county-level markets to drive sales growth through a dual-channel strategy of clinical and retail sales[161]. - The company is actively exploring industrial upgrade paths and second growth curves through the integration of industry and finance[104]. Research and Development - The company is investing RMB 50 million in R&D for new technologies related to drug formulation and production processes[31]. - The company plans to invest approximately 3% of its annual revenue into R&D to enhance its innovative capabilities[69]. - The company established the Panlong Pharmaceutical Research Institute in November 2018 to foster a collaborative "industry-university-research" platform[69]. - The company has implemented advanced production techniques, such as GMP standards, to ensure product quality across its health supplement range[67]. - The company has focused on expanding its market presence in orthopedics and rehabilitation, leveraging relationships with professional associations to drive brand growth[102]. Social Responsibility and Governance - The company is committed to social responsibility, investing in healthcare, education, and poverty alleviation through a charitable fund[12]. - The company emphasizes social responsibility while maximizing shareholder value, actively engaging with stakeholders to promote sustainable development[176]. - The company is committed to environmental protection and aims to create an ecological factory while exploring industrial tourism to enhance brand awareness[156]. - The company has a strong commitment to党建 (Party Building) to drive high-quality development, with 71 formal party members and a focus on integrating党建 into corporate governance[94]. Financial Management and Compliance - The company adheres to strict information disclosure regulations, ensuring transparency and protecting shareholder rights, particularly for minority shareholders[174]. - The company has established a dedicated investor relations management system, facilitating communication through various channels to ensure equal access to information for all shareholders[175]. - The company maintains an independent governance structure, ensuring that its operations are distinct from those of its controlling shareholders[180]. - The company has established a comprehensive financial accounting system, allowing for independent financial decision-making and tax compliance[184]. Market Trends and Opportunities - The company has identified significant growth opportunities in the traditional Chinese medicine sector, supported by government policies[49]. - The establishment of geriatric medicine departments in secondary and higher-level hospitals is expected to reach 60% by 2025, which will benefit the market for musculoskeletal system medications[52]. - The company is positioned to benefit from the increasing health awareness and the shift in healthcare spending from treatment to preventive care, particularly in the context of an aging population[56]. - The company faces risks from industry policy changes and plans to adapt its strategies to align with national healthcare reforms and regulations[159].